108 related articles for article (PubMed ID: 3687313)
1. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics.
Federlin KF; Mehlburger L; Hillebrand I; Laube H
Acta Diabetol Lat; 1987; 24(3):213-21. PubMed ID: 3687313
[TBL] [Abstract][Full Text] [Related]
2. The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
Hillebrand I; Boehme K; Graefe KH; Wehling K
Klin Wochenschr; 1986 Apr; 64(8):393-6. PubMed ID: 3517475
[TBL] [Abstract][Full Text] [Related]
3. The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
Kennedy FP; Miles JM; Heiling V; Gerich JE
Clin Exp Pharmacol Physiol; 1987 Aug; 14(8):633-40. PubMed ID: 3326689
[TBL] [Abstract][Full Text] [Related]
4. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
Schnack C; Röggla G; Luger A; Schernthaner G
Eur J Clin Pharmacol; 1986; 30(4):417-9. PubMed ID: 3527720
[TBL] [Abstract][Full Text] [Related]
5. Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
Joubert PH; Bam WJ; Manyane N
Eur J Clin Pharmacol; 1986; 30(2):253-5. PubMed ID: 3519244
[TBL] [Abstract][Full Text] [Related]
6. A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
Kennedy FP; Gerich JE
Clin Pharmacol Ther; 1987 Oct; 42(4):455-8. PubMed ID: 3311550
[TBL] [Abstract][Full Text] [Related]
7. Effect of two new alpha-glucosidase inhibitors in insulin-dependent diabetic patients.
Serrano-Rios M; Sabán J; Navascués I; Cañizo JF; Hillebrand I
Diabetes Res Clin Pract; 1988 Jan; 4(2):111-6. PubMed ID: 3277827
[TBL] [Abstract][Full Text] [Related]
8. Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Arends J; Willms BH
Horm Metab Res; 1986 Nov; 18(11):761-4. PubMed ID: 3539737
[TBL] [Abstract][Full Text] [Related]
9. A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Katsilambros N; Philippides P; Toskas A; Protopapas J; Frangaki D; Marangos M; Siskoudis P; Anastasopoulou K; Xefteri H; Hillebrand I
Arzneimittelforschung; 1986 Jul; 36(7):1136-8. PubMed ID: 3533089
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics.
Gerard J; Hillebrand I; Lefèbvre PJ
Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):483-8. PubMed ID: 3316059
[TBL] [Abstract][Full Text] [Related]
11. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
12. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
13. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
Madar Z
J Nutr; 1989 Dec; 119(12):2023-9. PubMed ID: 2695605
[TBL] [Abstract][Full Text] [Related]
14. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE
S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090
[TBL] [Abstract][Full Text] [Related]
15. Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Hatziagelaki E; Ladas S; Linos A; Hillebrand I; Raptis S
Eur J Clin Invest; 1988 Feb; 18(1):33-8. PubMed ID: 3130257
[TBL] [Abstract][Full Text] [Related]
16. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
[TBL] [Abstract][Full Text] [Related]
18. Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Raptis S; Raptis A; Hatziagelaki E; Mitrakou A; Halvatsiotis P; Ladas S; Hillebrand I
Klin Wochenschr; 1986 May; 64(9):405-10. PubMed ID: 3520133
[TBL] [Abstract][Full Text] [Related]
19. Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
Requejo F; Uttenthal LO; Bloom SR
Diabet Med; 1990 Jul; 7(6):515-20. PubMed ID: 2163805
[TBL] [Abstract][Full Text] [Related]
20. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Scott AR; Tattersall RB
Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
